Sarepta Therapeutics (SRPT) Posts Wider Q4 Loss; NDA Submission for Eteplirsen Planned for Mid-Year 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Sarepta Therapeutic (SRPT) PT Cut to $38 at Needham & Company; 'Buy' Maintained
March 2, 2015 8:43 AM ESTNeedham & Company analyst Chad Messer cut his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $38.00 (from $52.00) but maintained a Buy rating following Q4 results and news the company remains on track to file an NDA for eteplirsen in Duchenne's muscular dystrophy (DMD) by... More
Cowen Downgrades Sarepta Therapeutic (SRPT) to Market Perform
February 27, 2015 9:15 AM ESTCowen downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Outperform to Market Perform and removed its price target (prior $19.00).
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $13.82 yesterday.
... MoreBaird Maintains Neutral View on Sarepta Therapeutic (SRPT) Post Q4
February 27, 2015 9:07 AM ESTBaird analyst Brian Skorney reiterated a Neutral rating and $16 price target on Sarepta Therapeutic (NASDAQ: SRPT) following Q4 results.
Skorney commented, "No change to outlook following 4Q14. We're remaining on the sidelines here after the 4Q14 update didn't give us enough... More
